Psoriatic News and Research

RSS

Idera to present data from Phase 2 trial of IMO-3100 in patients with psoriasis at IID 2013

Idera Pharmaceuticals today announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements from baseline of up to 90% in Psoriasis Area Severity Index scores in patients with moderate to severe plaque psoriasis following four weeks of treatment with the Toll-like Receptor antagonist IMO-3100.

8 May 2013

Study: Use of anti-TNF therapies in RA patients does not increase risk of herpes zoster

Patients with rheumatoid arthritis (RA) who initiated use of anti-tumor necrosis factor therapies were not at a higher risk of developing herpes zoster (shingles), compared with patients who initiated nonbiologic treatment regimens, according to research from the University of Alabama at Birmingham (UAB) and the Oregon Health and Science University. The findings appeared in the March 6, 2013, issue of the Journal of the American Medical Association (JAMA).

22 Apr 2013

Patients with psoriasis carry increased risk of developing severe co-morbid conditions

The International Federation of Psoriasis Associations, IFPA, commends the World Health Organization for raising awareness of the risks associated with high blood pressure and calls for healthcare professionals to regularly scan for the condition in patients with psoriasis.

9 Apr 2013

RA patients who initiate anti-TNF therapies do not have higher risk of shingles: Study

Although patients with rheumatoid arthritis have a disproportionately higher incidence of herpes zoster (shingles), an analysis that included nearly 60,000 patients with RA and other inflammatory diseases found that those who initiated anti-tumor necrosis factor therapies were not at higher risk of herpes zoster compared with patients who initiated nonbiologic treatment regimens, according to a study appearing in the March 6 issue of JAMA.

7 Mar 2013

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013

Children with psoriasis at increased risk for obesity

Children with psoriasis have a greater risk for being overweight or obese than those without the disorder, report researchers.

23 Nov 2012

Abbott receives FDA approval for Humira to treat ulcerative colitis

The U.S. Food and Drug Administration today expanded the approved use of Humira (adalimumab) to include treatment of moderate-to-severe ulcerative colitis in adults.

29 Sep 2012

TNF inhibitors best cardiac option for psoriasis patients

Use of tumor necrosis factor inhibitors is associated with a significantly reduced risk for myocardial infarction in psoriasis patients compared with use of other medications, report researchers.

31 Aug 2012

FDA approves Horizon Pharma's RAYOS to treat key IL-6 mediated diseases

Horizon Pharma, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved RAYOS (prednisone) delayed-release tablets (1 mg, 2 mg and 5 mg) to treat a broad range of diseases including rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma and chronic obstructive pulmonary disease (COPD).

26 Jul 2012

Herpes zoster vaccine recommendations questioned in patients on biologics

Administration of the live attenuated herpes zoster vaccine is not associated with an increased risk for shingles shortly after vaccination in patients receiving biologic treatments for immune-mediated diseases, researchers report in JAMA.

10 Jul 2012

Live zoster vaccine associated with reduced risk of HZ in patients with immune-mediated diseases

Although some have suggested that patients receiving medication for immune-mediated diseases such as rheumatoid arthritis or psoriasis may be at increased risk of herpes zoster (HZ; shingles) shortly after receipt of the vaccine, an analysis that included nearly 20,000 vaccinated Medicare beneficiaries finds that the live zoster vaccine is not associated with an increased risk of HZ shortly after vaccination in patients currently treated with biologics, and that it is associated with a significantly reduced longer-term risk of HZ in patients with an immune-mediated disease, according to a study in the July 4 issue of JAMA.

4 Jul 2012

Shingles vaccine may not increase risk of varicella in people with auto-immune diseases

New research from the University of Alabama at Birmingham casts doubt on the long-standing belief that the vaccine for shingles should not be given to patients taking biologics for auto-immune diseases such as rheumatoid arthritis.

4 Jul 2012

Psoriasis TNF-α therapeutic effects mediated by MSC antioxidant reduction

The therapeutic effects of tumor necrosis factor-α inhibitors in psoriasis occur through a reduction in the antioxidant response of mesenchymal stem cells, suggest study findings.

15 Jun 2012

Psoriasis link with autoimmune diseases underscored

Patients with psoriasis are nearly twice as likely to have an autoimmune disease as individuals without the condition, suggest study findings.

8 Jun 2012

Drinking alcohol linked to skin disorder

Regularly drinking alcohol, particularly in higher quantities, appears to increase the risk for developing psoriasis, the results of a Chinese study suggest.

8 Jun 2012

Hypocaloric diet may help achieve minimal disease activity in psoriatic arthritis patients

According to a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, patients with psoriatic arthritis (PsA) who are starting anti-tumour necrosis factor (anti-TNF) treatment and adhere to a hypocaloric diet have a significantly greater chance of achieving minimal disease activity (MDA, an important measure of disease activity) at six months compared to those on a standard diet.

8 Jun 2012

STELARA effectively reduces signs and symptoms of active psoriatic arthritis

Patients with active psoriatic arthritis receiving the interleukin (IL)-12/23 inhibitor STELARA (ustekinumab) experienced significant improvements in signs and symptoms of the disease, according to new findings presented today from a Janssen Research & Development, LLC, (Janssen)-sponsored investigational study.

6 Jun 2012

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

Abbott scientists and independent researchers will highlight the latest investigational research findings on HUMIRA (adalimumab) at the European League Against Rheumatism (EULAR) Congress in Berlin, Germany, from 6-9 June, 2012.

29 May 2012

National Psoriasis Foundation awards more than $2 million for research

Twenty-six scientists have received a total of $2.06 million in grants from the National Psoriasis Foundation to study psoriasis—the most common autoimmune disease in the country, affecting as many as 7.5 million Americans—and psoriatic arthritis, an inflammatory joint and tendon disease.

16 May 2012

Rare CARD14 gene mutations can lead to plaque psoriasis

Scientists led by Washington University School of Medicine in St. Louis have identified the first gene directly linked to the most common form of psoriasis, a chronic skin condition.

20 Apr 2012

Psoriatic News and Research

Idera to present data from Phase 2 trial of IMO-3100 in patients with psoriasis at IID 2013

Study: Use of anti-TNF therapies in RA patients does not increase risk of herpes zoster

Patients with psoriasis carry increased risk of developing severe co-morbid conditions

RA patients who initiate anti-TNF therapies do not have higher risk of shingles: Study

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

Children with psoriasis at increased risk for obesity

Abbott receives FDA approval for Humira to treat ulcerative colitis

TNF inhibitors best cardiac option for psoriasis patients

FDA approves Horizon Pharma's RAYOS to treat key IL-6 mediated diseases

Herpes zoster vaccine recommendations questioned in patients on biologics

Live zoster vaccine associated with reduced risk of HZ in patients with immune-mediated diseases

Shingles vaccine may not increase risk of varicella in people with auto-immune diseases

Psoriasis TNF-α therapeutic effects mediated by MSC antioxidant reduction

Psoriasis link with autoimmune diseases underscored

Drinking alcohol linked to skin disorder

Hypocaloric diet may help achieve minimal disease activity in psoriatic arthritis patients

STELARA effectively reduces signs and symptoms of active psoriatic arthritis

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

National Psoriasis Foundation awards more than $2 million for research

Rare CARD14 gene mutations can lead to plaque psoriasis

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News